<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010772</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0237</org_study_id>
    <secondary_id>NCI-2021-08496</secondary_id>
    <secondary_id>2021-0237</secondary_id>
    <nct_id>NCT05010772</nct_id>
  </id_info>
  <brief_title>Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission</brief_title>
  <official_title>Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib trial is to find out the side effects and possible benefits of decitabine alone&#xD;
      or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating&#xD;
      patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs,&#xD;
      such as decitabine, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading.&#xD;
      Venetoclax may stop the growth of cancer cells by blocking a protein called Bcl-2 needed for&#xD;
      cell growth. Gilteritinib, enasidenib, and ivosidenib may stop the growth of cancer cells by&#xD;
      blocking some of the enzymes needed for cell growth. Giving decitabine alone or together with&#xD;
      venetoclax, gilteritinib, enasidenib, or ivosidenib may help to control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess safety of patients with acute myeloid leukemia (AML) treated with decitabine and&#xD;
      cedazuridine (oral decitabine)-based combinations as maintenance therapy after achieving&#xD;
      remission.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess relapse-frees survival (RFS) of patients with AML treated with oral&#xD;
      decitabine-based combinations as maintenance therapy.&#xD;
&#xD;
      II. To assess overall survival (OS) of patients with AML treated with oral decitabine-based&#xD;
      combinations as maintenance therapy.&#xD;
&#xD;
      III. To assess event-free survival (EFS) of patients with AML treated with oral&#xD;
      decitabine-based combinations as maintenance therapy.&#xD;
&#xD;
      IV. To assess the duration of remission (CRd) of patients with AML treated oral&#xD;
      decitabine-based combinations as maintenance therapy.&#xD;
&#xD;
      V. To assess the effects of oral decitabine-based combinations on dynamics of minimal&#xD;
      residual disease and their relationship to outcomes.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate RFS in (1) intensive induction cohort and (2) lower intensity induction&#xD;
      cohort.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 5 arms.&#xD;
&#xD;
      ARM A: Patients receive decitabine and cedazuridine orally (PO) once daily (QD) on days 1-3.&#xD;
      Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on&#xD;
      days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      ARM C: Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD&#xD;
      on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      ARM D: Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on&#xD;
      days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      ARM E: Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on&#xD;
      days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6-12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Safety analyses in general will be descriptive and will be presented in tabular format with the appropriate summary statistics. Adverse events will be tabulated using frequency and percentage by severity and by relations to the treatments for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>From complete remission or complete remission with incomplete count recovery until date of first objective documentation of relapse or death, assessed up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate RFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of treatment start until date of death due to any cause, assessed up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From treatment start until date of first documented event., assessed up to 5 years</time_frame>
    <description>Event will be defined as: confirmed relapse, withdrawal from study due to adverse event, or death due to any cause. The Kaplan-Meier method will be used to estimate EFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used to duration of remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The log rank test and Cox proportional hazards model will be used to evaluate the association between the time to event outcomes and status of residual disease.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>RFS (Intensive induction cohort)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate RFS for intensive induction cohort.</description>
  </other_outcome>
  <other_outcome>
    <measure>RFS (Lower intensity induction cohort)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier method will be used to estimate RFS for lower intensity induction cohort.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (decitabine and cedazuridine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine and cedazuridine PO QD on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (decitabine and cedazuridine, venetoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (decitabine and cedazuridine, gilteritinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (decitabine and cedazuridine, enasidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (decitabine and cedazuridine, ivosidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine and Cedazuridine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (decitabine and cedazuridine)</arm_group_label>
    <arm_group_label>Arm B (decitabine and cedazuridine, venetoclax)</arm_group_label>
    <arm_group_label>Arm C (decitabine and cedazuridine, gilteritinib)</arm_group_label>
    <arm_group_label>Arm D (decitabine and cedazuridine, enasidenib)</arm_group_label>
    <arm_group_label>Arm E (decitabine and cedazuridine, ivosidenib)</arm_group_label>
    <other_name>ASTX727</other_name>
    <other_name>C-DEC</other_name>
    <other_name>CDA Inhibitor E7727/Decitabine Combination Agent ASTX727</other_name>
    <other_name>Cedazuridine/Decitabine Combination Agent ASTX727</other_name>
    <other_name>Cedazuridine/Decitabine Tablet</other_name>
    <other_name>DEC-C</other_name>
    <other_name>Inqovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm D (decitabine and cedazuridine, enasidenib)</arm_group_label>
    <other_name>AG-221</other_name>
    <other_name>CC-90007 Free Base</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (decitabine and cedazuridine, gilteritinib)</arm_group_label>
    <other_name>ASP-2215</other_name>
    <other_name>ASP2215</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivosidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm E (decitabine and cedazuridine, ivosidenib)</arm_group_label>
    <other_name>AG-120</other_name>
    <other_name>Tibsovo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (decitabine and cedazuridine, venetoclax)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &gt;= 18 years AML who have achieved their FIRST complete response (CR) or&#xD;
             complete response with incomplete bone marrow recovery (CRi) and are not immediately&#xD;
             candidates for allogeneic stem cell transplant&#xD;
&#xD;
          -  Patients who have received intensive therapy (defined as receiving standard or higher&#xD;
             dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received&#xD;
             remission induction therapy and at least 1 consolidation cycle. These patients are&#xD;
             eligible as long as they are not greater than 2 months from their last consolidation&#xD;
             therapy and will be designated as COHORT 1 (intensive induction cohort)&#xD;
&#xD;
          -  Patients who have received lower intensity therapy (defined as receiving low-dose&#xD;
             cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission&#xD;
             should have received at least 2 cycles of lower intensity therapy between the time&#xD;
             they have achieved CR/CRi and enrollment on this protocol. They will be designated as&#xD;
             COHORT 2 (lower intensity induction cohort)&#xD;
&#xD;
          -  For either subgroup (lower or higher intensity), patients who have measurable residual&#xD;
             disease may be enrolled on their respective cohort at any time without maximum 'time&#xD;
             from consolidation' requirement&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt; or = 3&#xD;
&#xD;
          -  Serum total bilirubin &lt; or = to 1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine &lt; or = to 2.5 x ULN&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 0.5 x k/uL&#xD;
&#xD;
          -  Platelet count &gt; or = 50 x k/uL&#xD;
&#xD;
          -  For females of childbearing age, they may participate if they:&#xD;
&#xD;
               -  Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling&#xD;
&#xD;
               -  Agree to either abstinence or 2 effective contraceptive methods (such as barrier&#xD;
                  methods or hormonal contraception) throughout the treatment period and up to 30&#xD;
                  days after discontinuing treatment&#xD;
&#xD;
          -  For male patients with a female partner of childbearing age, they may participate if&#xD;
             they agree to either abstinence or 2 effective contraceptive methods throughout the&#xD;
             treatment period and up to 30 days after discontinuing treatment&#xD;
&#xD;
          -  Ability to understand and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British&#xD;
             (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics&#xD;
             studies&#xD;
&#xD;
          -  Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also&#xD;
             ineligible unless they are unable or unwilling to receive therapy with a tyrosine&#xD;
             kinase inhibitor&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to active uncontrolled&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Patients with active CNS (central nervous system) disease&#xD;
&#xD;
          -  Patients with documented hypersensitivity to any components of the study program&#xD;
&#xD;
          -  Females who are pregnant or lactating or intending to become pregnant during the study&#xD;
&#xD;
          -  Patients with history of extramedullary AML, except for CNS involvement that is&#xD;
             currently controlled, will not be eligible for enrollment&#xD;
&#xD;
          -  Patient should be removed from current trial if they wish to participate and get&#xD;
             treatment on another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tapan M Kadia</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tapan M. Kadia</last_name>
      <phone>713-792-7305</phone>
      <email>tkadia@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Tapan M. Kadia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Ivosidenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

